Amy Nelson

Assistant Professor

CB 118


Dr. Nelson (who prefers Amy) has been a nurse since 1991, working in oncology, public health, clinical research, and education. Her work has taken her from Anoka County Public Health to the National Institutes of Health and the University of Maryland’s Institute of Human Virology, where she managed the Clinical Research Unit. Her undergraduate studies were at Bethel University in Community Health and Nursing, her Masters in Health Services Leadership & Management at the University of Maryland, Baltimore (UMB), and her doctorate at UMB with a dissertation about the impact of moderate walking on frailty in people living with HIV, focusing on mitochondrial capacity. Dr. Nelson also spent ten years working for an international non-profit in inner-city San Francisco, managing staff, students, and volunteers while leading groups of students on eight-week international urban volunteer service trips. Dr. Nelson came to Augsburg in 2022, is a coordinator for the Health Commons, and a weekly participant in the Augsburg Central Health Commons and Health Commons East.


  • PhD Nursing, University of Maryland, Baltimore (UMB)
  • Certificate: Teaching in Nursing & Health Professions, UMB
  • MS: Health Services Leadership & Management, UMB
  • BSN, Bethel University, St. Paul, MN
  • BS: Community Health, Bethel University, St. Paul, MN

Areas of Teaching Responsibility

  • Nursing Research
  • Nursing Leadership
  • Concepts of Civic Agency

Presentations & Publications

  • Martin, K & Nelson, A.K. (October 2023). The Augsburg Health Commons: Teaching Transcultural Nursing While Caring for Those Who Experience Marginalization 49th Annual Conference Transcultural Nursing Society, Charleston, South Carolina
  • Nelson, A.K. (March 2020). Altering Mechanisms of Frailty in Persons Living with HIV.
    42nd Annual Graduate Research Conference, University of Maryland, Baltimore
  • Nelson, A.K. (November 2018). Panelist: Top Tips for Successful Grant Proposal United Conference of Hepatogastroenterology and Infectious Diseases 2018, Cairo Egypt
  • Nelson, A.K. (November 2013). Impact of Pre-Existing Mental Health Disorders on Adherence and Sustained Virologic Response with an Interferon-Free Trial of Sofosbuvir and Ribavirin for Chronic Hepatitis C. Hepatology Associates Course. American Association for the Study of Liver Diseases.
  • Clark, K., Nelson, A.K., Martin K., Ullery, M. (2024) Catalyst for change: Evaluating the impact of the citizen nurse education,” (JNE-2023-767R1, Research Brief), Journal of Nursing Education, accepted for publication.
  • Klinedinst, N. J., Huang, W., Nelson, A. K., Resnick, B., Renn, C., Kane, M. A., & Dorsey, S. G. (2023). Protein changes After 6 weeks of walking and the relationship to pain in adults with knee osteoarthritis. Biological Research for Nursing, 25(1), 65-75.
  • Price, A. S., Nelson, A. K., Ghosh, A., Kottilil, S., & Chua, J. V. (2023). A phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection. Journal of Medical Virology, 95(1), e28105.
  • Klinedinst, N. J., Huang, W., Nelson, A. K., Resnick, B., Renn, C., Kane, M. A., & Dorsey, S. G. (2022). Inflammatory and immune protein pathways are possible mechanisms for pain following walking in knee osteoarthritis. Nursing Research, 71(4), 328-335.
  • Nelson, A.K., Fiskum, G., Renn, C., Zhu, S., Kottilil, S., Klinedinst, N.J. (2022). Mechanisms of musculoskeletal frailty in people living with HIV. The Journal of Frailty & Aging, 11(1):83-90.
  • Chua, J., Davis, C., Husson, J.S., Nelson, A., Lam, K.W., Mutumbi, L., Gilliam, B.L., DeVico, A.L., Lewis, G.K., Gaoo, R.C., Sajadi, M.M. (2021). Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 39(29):3879-3891. 10.1016/j.vaccine.2021.05.090
  • Romani, S., Stafford, K., Nelson, A., Bagchi, S., Kottilil, S. & Poonia, B. (2019).  Peripheral PD-1+ T cells co-expressing inhibitory receptors predict SVR with ultra short duration DAA therapy in HCV infection.  Frontiers in Immunology, 10 (1470).
  • Mathur, P., Comstock, E., Makuza, J. D., Emmanuel, B., Sebeza, J., Kiromera, A., Wilson, E.; Kattakuzhy, S.; Nelson, A; Kottilil, S. & Riedel, D. J. (2019). Implementation of a unique hepatitis C care continuum model in Rwanda. Journal Of Public Health, 41(2) e203-e208.
  • Townsend, K., Petersen, T., Gordon, L. A., Kohli, A., Nelson, A., Seamon, C.; Gross, C.; Tang, L; Osinusi, A.; Polis, M.A.; Masur, H & Kottilil, S. (2016). Effect of HIV co-infection on adherence to a 12- week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS, 30(2), 261-266.
  • Tang, L. S. Y., Masur, J., Sims, Z., Nelson, A., Osinusi, A., Kohli, A., Kattakuzhy, S.; Polis, M. & Kottilil, S. (2016). Safe and effective sofosbuvir-based therapy in patients with mental health disease on hepatitis C virus treatment. World Journal of Hepatology, 8(31), 1318–1326.
  • Kattakuzhy, S., Wilson, E., Sidharthan, S., Sims, Z., McLaughlin, M., Price, A; Silk, R.; Gross, C.; Akoth, E.; McManus, M.; Emmanuel, B.; Shrivastava, S.; Tang, L.; Nelson, A.; Teferi, G.; Chavez, J.; Lam, B.; Mo, H.; Osinusi, A.; Polis, M.; Masur, H.; Kohli, A. & Kottilil, S. (2016).  Moderate sustained virologic response rates with 6-week combination directly acting anti–Hepatitis C virus therapy in patients with advanced liver disease.  Clinical Infectious Diseases, 62(4), 440-447.
  • Wilson, E. M., Kattakuzhy, S., Sidharthan, S., Sims, Z., Tang, L., McLaughlin, M., Price, A., Nelson, A., Silk, R., Gross, C., Akoth, E., Mo, H., Subramanian, G.M., Pang, P.S., McHutchinson, J.G., Osinusi, A.,Masur, H., Kohli, A. & Kottilil, S. (2016). Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clinical Infectious Diseases, 62(3), 280-288.
  • Petersen, T., Townsend, K., Gordon, L. A., Sidharthan, S., Silk, R., Nelson, A.; Gross, C.; Calderon, M.; Proschan, M.; Osinusi, A.; Polis, M.A.; Masur, H.; Kottilil, S. & Kohli, A. (2016). High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatology International, 10(2), 310-319.
  • Kohli, A., Kattakuzhy, S., Sidharthan, S., Nelson, A., McLaughlin, M., Seamon, C., Wilson, E.; Meissner, E.G., Sims, Z.; Silk, R.; Gross, C.; Akoth, E.; Tang, L.; Price, A.; Jolley, T.A.; Emmanuel, B.; Proschan, M.; Teferi, G.; Chavez, J.; Abbott, S.; Osinusi, A.; Mo, H.; Polis, M.A.; Masur, H. & Kottilil, S. (2015). Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: An open-label, nonrandomized trial. Annals of Internal Medicine, 163(12), 899-907.
  • Kohli A., Kapoor R., Sims Z., Nelson A., Sidharthan S., Lam B., Silk, R.; Kotb, C.; Gross, C.; Teferi, G.; Sugarman, K.; Pang, P.S.; Osinusi, A.; Polis, M.A.; Rustgi, V.; Masur, H. & Kottilil S. (2015). Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of- concept, single-centre, open-label phase 2a cohort study. Lancet Infectious Diseases. 15(9):1049-54.
  • Sidharthan S., Kohli A., Sims Z., Nelson A., Osinusi A., Masur H., Kottilil, S. (2015). Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. Clinical Infectious Diseases. 60(12):1743-51.
  • Osinusi A., Townsend K., Kohli A., Nelson A., Seamon C., Meissner E.G.; Bom, D.; Silk, R.; Gross, C.; Price, A.; Sajadi, M.; Sidharthan, S.; Sims, Z., Herrmann, E.; Hogan, J.; Teferi, G.; Talwani, R.; Proschan, M.; Jenkins, V.; Kleiner, D.E.; Wood, B.J.; Subramanian, G.M.; Pang, P.S.; McHutchinson, J.G.; Polis, M.A.; Fauci, A.S.; Masur, H. & Kottilil S. (2015). Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Journal of the American Medical Association. 313(12):1232-9.
  • Kohli A., Osinusi A., Sims Z., Nelson A., Meissner E.G., Barrett L.L.; Bon, D.; Marti, M.M.; Silk, R.; Kotb, C.; Gross, C.; Jolley, T.A.; Sidharthan, S.; Petersen, T.; Townsend, K.; Egerson, D.; Kapoor, R.; Spurlin, E.; Sneller, M.; Proschan, M.; Herrmann, E.; Kwan, R.; Teferi, G.; Talwani, R.; Diaz, G.; Kleiner, D.E.; Wood, B.J.; Chavez, J.; Abbott, S.; Symonds, W.T.; Subramanian, G.M..; Pang, P.S.; McHutchinson, J.; Polis, M.A.; Fauci, A.S.; Masur, H. & Kottilil S. (2015). Virological response after 6-week triple-drug regimens for hepatitis C: A proof-of-concept phase 2A cohort study. Lancet. 385(9973):1107-13.
  • Osinusi A., Kohli A., Marti M.M., Nelson A., Zhang X., Meissner E.G., Silk, R.; Townsend, K.; Pang, P.S.; Subramanian, G.M.; McHutchinson, J.G.; Fauci, A.S.; Masur, H. & Kottilil S. (2014).  Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: An open-label pilot study. Annals of Internal Medicine. 161(9):634-8.
  • Narayanan, S., Townsend, K., Macharia, T., Majid, A., Nelson, A., Redfield, R. R.; Kottilil, S.; Talwani, R. & Osinusi, A. (2014). Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis C. Hepatology International, 8(4), 560-566. https://10.1007/s12072-014- 9574-0
  • Kardava L., Moir S., Shah N., Wang W., Wilson R., Buckner C.M.; Santich, B.H.; Kim, L.J.Y.; Spurlin, E.S.; Nelson, A.K.; Wheatley, A.K.; Harvey, C.J.; McDermott, A.B.; Wucherpfennig, K.W.; Chun, T-C.; Tsang, J.S.; Li, Y. & Fauci, A.S. (2014). Abnormal B cell memory subsets dominate HIV-specific responses in infected individuals. The Journal of Clinical Investigation, 124(7):3252-62.
  • Buckner C.M., Moir S., Kardava L., Ho J., Santich B.H., Kim L.J., Funk, E.K.; Nelson, A.K., Winckler, B., Chairez, C.L., Theobald-Whiting, N. L., Anaya-O’Brien, S., Alimchandani, M., Quezado, M.M., Yao, M.D., Kovacs, J.A., Chun, T-W., Fauci, A.S., Malech, H.L. & DeRavin, S.S. (2014). CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. Journal of Allergy and Clinical Immunology, 133(6): 1676-1685.
  • Osinusi, A., Bon, D., Nelson, A., Lee, Y.J., Poonia, S., Shivakumar, B., Cai, S.Y.; Wood, B.; Haqgmans, B.; Lempicki, R.; Herrmann, E.; Sneller, M.; Polis, M.; Masur, H. & Kottilil S. (2014). Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients. Journal of Medical Virology,  86(2):177-85.
  • Meissner, E.G.; Nelson, A., Marti, M., Masur, H., Osinusi, A., Kottilil, S. (2014). Sustained virologic response for chronic hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin.  Open Forum Infectious Diseases 1(1).
  • Funk, E.K., Shaffer A., Shivakumar, B., Sneller, M., Polis, M.A., Masur, H. Heytens, L.; Nelson, A.; Kwan, R.; Kottilil, S. & Kohli, A. (2013). Short communication: Interferon/ribavirin treatment for HCV is associated with the development of hypophosphatemia in HIV/hepatitis C virus-coinfected patients. AIDS Research and Human Retroviruses, 29(9):1190-4.
  • Osinusi A., Meissner E.G., Lee Y.J., Bon D., Heytens L., Nelson A., Sneller, M., Kohli, A., Barrett, L., Proschan, M., Herrmann, E., Shivakumar, B., Gu, W.,  Kwan, R., Teferi, G.;, Talwani, R., Silk, R., Kotb, C., Wroblewski, S., Fishbein, D., Dewar, R., Highbarger, H., Zhang, X., Kleiner, D., Wood, B.J., Chavez, J., Symonds, W.T., Subramanian, M., McHutchinson, J, Polis, M.A., Fauci, A. S.. Masur, H. & Kottilil S. (2013). Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial. Journal of the American Medical Association,  310(8):804-11.
  • Buckner, C.M.; Moir, S.; Ho, J.; Wang, W.; Posada, J.G.; Kardava, L.; Funk, E.; Nelson, A.K.; Li, Y.; Chun, T-W. & Fauci, A.S. (2013). Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation. Journal of Virology, 87(10):5800-11.
  • Imamichi, H., Lempicki, R.A., Adelsberger, J.W., Hasley, R.B., Rosenberg, A., Roby, G., Rehm, C.A., Nelson, A., Krishnan, S., Pavlick, M., Woods, C.J., Baseler, M.W. & Lane, H.C. (2012). The CD8+ HLA-DR+ T cells expanded in HIV-1 infection are qualitatively identical to those from healthy controls. European Journal of Immunology, 42(10):2608-20.
  • Blazkova, J., Chun, T.W., Belay, B.W., Murray, D., Justement, J.S., Funk, E.K., Nelson, A., Hallahan, C.W., Moir, S., Wender, P.A. & Fauci, A.S. (2012). Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. Journal of Infectious Diseases, 206(5):765-9.
  • Blazkova, J.; Murray, D.; Justement, J.S.; Funk, E.K.; Nelson, A.K.; Moir, S.; Chun, T-W. & Fauci, A.S. (2012).  Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy. Journal of Virology, 86(9):5390-2.

Current Certifications

  • Public Health Nursing
  • Registered Nurse